Multicenter Phase II Trial of YM155, a Small-Molecule Suppressor of Survivin, in Patients With Advanced, Refractory, Non–Small-Cell Lung Cancer

  • Giuseppe Giaccone
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.
  • Petr Zatloukal
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.
  • Jaromir Roubec
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.
  • Karijn Floor
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.
  • Jaromir Musil
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.
  • Milan Kuta
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.
  • Rob J. van Klaveren
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.
  • Subhash Chaudhary
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.
  • Adrie Gunther
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.
  • Setareh Shamsili
    From the Vrije Universiteit Medical Center, Amsterdam; Erasmus Medical Center, Rotterdam; Astellas Pharma Europe BV, Leiderdorp, the Netherlands; Charles University, 3rd Faculty of Medicine and Teaching Hospital Bulovka; Charles University, 2nd Faculty of Medicine and Teaching Hospital Motol, Prague; Teaching Hospital Ostrava-Poruba, Ostrava-Poruba; Nemocnice Chomutov, Chomutov; and the Onkologicke Centrum JG Mendla, Novy Jicin, Czech Republic.

この論文をさがす

説明

<jats:sec><jats:title>Purpose</jats:title><jats:p> To evaluate the antitumor activity and safety of YM155, a novel, small-molecule suppressor of survivin, as single-agent therapy in patients with previously treated, advanced non–small-cell lung cancer (NSCLC). </jats:p></jats:sec><jats:sec><jats:title>Patients and Methods</jats:title><jats:p> Patients with stage IIIb/IV NSCLC who had experienced treatment failure during one or two prior chemotherapy regimens (at least one of which was platinum based) received YM155 as a continuous intravenous infusion (4.8 mg/m<jats:sup>2</jats:sup>/d) over 168 hours followed by observation for 14 days in 21-day treatment cycles. The primary end point was objective tumor response rate (ORR). Secondary end points included duration of stable disease (SD), progression-free survival (PFS), overall survival (OS), safety and pharmacokinetic profiles, and pharmacodynamic evaluations. </jats:p></jats:sec><jats:sec><jats:title>Results</jats:title><jats:p> Thirty-seven patients received YM155. Two patients achieved a confirmed partial response, with an ORR of 5.4% (95% CI, 0.7% to 18.2%). An additional 14 patients (37.8%) achieved SD resulting in a disease control rate of 43.2% (95% CI, 27.1% to 60.5%). Median duration of PFS was 1.7 months (95% CI, 1.3 to 2.8 months). Median duration of OS was 6.6 months (95% CI, 4 to 12.2 months), with a 1-year survival rate of 35.1%. Treatment with YM155 was well tolerated with the majority of treatment discontinuations not treatment related. </jats:p></jats:sec><jats:sec><jats:title>Conclusion</jats:title><jats:p> YM155 exhibited modest single-agent activity in patients with refractory, advanced NSCLC. A favorable safety/tolerability profile was reported. Further evaluation of YM155 in combination with chemotherapy and other targeted agents may be warranted. </jats:p></jats:sec>

収録刊行物

被引用文献 (9)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ